News

Used to treat fungus infections, the Ultramicrosize Griseofulvin tablets had sales nearly of $16.7m for the twelve months ended 30 June 2012 in the US market, according to

According to the pre-clinical research alliance, CFFT will spend $58m to advance the drug candidates into clinical trials by the end of agreement period of six years. CF

The company submitted a supplemental new drug application (sNDA) based on the data from randomized, controlled Phase 3 EURTAC trial conducted in patients with EGFR triggering mutation-positive advanced

Promacta, brand name of eltrombopag in the US, will enable thrombocytopenia patients suffering from chronic hepatitis C to commence and sustain interferon-based therapy. GlaxoSmithKline oncology president Paolo Paoletti

Clontech researchers, who have participated in SnapGene beta testing, have also assisted SnapGene’s developers on the interface and functionality, which includes SnapGene’s ability to simulate Clontech’s In-Fusion cloning.

Subsequent to the Phase I patient safety data review, a Safety Monitoring Committee authorised the enrolment for the consequential Phase II study. Phase II trial is expected to

The FDA acceptance was based on the comparability data of Mesoblast’s initial set of manufacturing runs for clinical product to be used in the upcoming Phase 3 trial

The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices. In 2000 Pardonge served as R&D manager for Aptar Pharma’s prescription division and promoted

Net sales for third quarter of 2012 were $9.97m compared to $24.78m for the third quarter of 2011. The company reported a net loss of $13.25m, or $1.41